Pfizer has released top-line results from two Phase III trials of tofacitinib, an oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. The company is currently running five Phase III trials in this area, under the Oral Psoriasis Treatment (OPT) program. The reported trials were OPT Compare and OPT Retreatment. OPT Compare is a 12-week, non-inferiority study comparing the efficacy and safety of tofacitinib 5 an...